RxDoctor Payments Data

Keith Mankowitz, MD

Cardiovascular Disease · Chesterfield, MONPI 1598783938

Payments from drug & device makers

$16,479in general payments, 2019–2025

Across 652 payments — averaging $25.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sanofi-aventis U.S. LLC$6K
  • Novartis$1K
  • Regeneron Healthcare Solutions, Inc.$1K
  • Amgen$925
  • Boston Scientific$847
  • Merck$600
  • plus $6K from 45 others

What the payments were for

  • Speaking & faculty fees$6,06437%
  • Travel & lodging$120%
  • Food & beverage$10,19462%
  • Education$2091%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$16,479 in reported general payments places this provider in the 75th percentile of 391 cardiovascular disease providers in Missouri.

See all cardiovascular disease providers in Missouri

Medicare billing

Part B allowed, 2024
$280,703
Medicare patients
1,042
Services billed
2,738

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban1,118$1,079,399
VyndamaxTafamidis34$823,621
EntrestoSacubitril/Valsartan422$458,486
CamzyosMavacamten40$325,932
XareltoRivaroxaban249$251,366
Repatha SureclickEvolocumab286$213,392
FarxigaDapagliflozin Propanediol241$206,937
JardianceEmpagliflozin161$141,759
Praluent PenAlirocumab152$108,170
VascepaIcosapent Ethyl103$56,665
MultaqDronedarone Hcl28$38,393
OzempicSemaglutide34$34,379
NexletolBempedoic Acid35$28,004
BrilintaTicagrelor20$21,722
EdarbyclorAzilsartan Med/Chlorthalidone38$20,156

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Vyndamax$534$1,903,0211,152 claims
NovartisEntresto$1,322$458,486422 claims
E.r. Squibb & Sons, L.L.C.Camzyos$281$325,93240 claims
Johnson & JohnsonXarelto$557$251,366249 claims
AstraZenecaFarxiga, Brilinta$543$228,659261 claims
Boehringer IngelheimJardiance$281$141,759161 claims
Novo NordiskOzempic, Wegovy$425$51,48147 claims
Esperion Therapeutics, Inc.Nexletol, Nexlizet$338$45,12970 claims
Sanofi-aventis U.S. LLCMultaq$5,624$38,39328 claims
Arbor Pharmaceuticals, Inc.Edarbyclor, Edarbi$24$38,25065 claims
Lexicon Pharmaceuticals, Inc.Inpefa$35$7,75213 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 391 cardiovascular disease providers in Missouri.

Other cardiovascular disease in Chesterfield

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →